IntelGenx Corp. Forms Strategic Alliance with Dava Pharmaceuticals to Develop Cardiovascular Product Addressing a U.S. Market of $1.0 Billion

April 14, 2008

SAINT LAURENT, QUEBEC--(Marketwire - April 14, 2008) - IntelGenx Corp. (OTCBB:IGXT) ("IntelGenx" or the "Company") has formed a strategic alliance with DAVA Pharmaceuticals Inc (“DAVA”) to develop and commercialize a generic equivalent to a major cardiovascular product using IntelGenx's proprietary VersaTab™ delivery technology.

Horst G. Zerbe, President and CEO of IntelGenx, said, "This alliance illustrates IntelGenx’ business strategy whereby we seek out key commercialization partners for development of products with significant potential using our drug delivery technologies."

Under the strategic alliance, the companies expect to launch the product in the fourth quarter of 2010.  IntelGenx will complete the development of the product, using its patented proprietary delivery technologies.  IntelGenx will be entitled to fees for the development of the product as well as recurring revenue through a share of DAVA’s U.S. gross profit.  DAVA will be responsible for commercialization and marketing activities in the U.S.

According to Datamonitor’s Pharmaceuticals and Healthcare Knowledge Center, the peak U.S. sales for the brand exceeded $1.0 billion annually. IntelGenx management anticipates rapid penetration of the market, achieving significant sales over the first five years of commercialization.

Dr. Zerbe stated, "We are indeed pleased to partner with DAVA, a rapidly growing generic company noted for its strong strategic collaborations with leading Active Pharmaceutical Ingredient (“API”) suppliers, branded pharmaceutical companies, and generic product developers and manufacturers. Our innovative oral, immediate-release and controlled-release delivery technologies add important new options to their portfolio."

IntelGenx now has nine  products in development with its first product (pre-natal vitamin) to be commercialized in the second half (H2) of 2008.  In addition, the Company expects to engage in additional development and commercial alliances thereby expanding their product pipeline with new and existing partnerships in 2008.
About IntelGenx Corp.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company's research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension, and smoking cessation. More information is available about the company at www.intelgenx.com.
About DAVA Pharmaceuticals

DAVA Pharmaceuticals, a specialty pharmaceuticals company, is focused on developing and marketing a broad portfolio of pharmaceutical products. DAVA is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. DAVA’s headquarters is in Fort Lee, New Jersey. For further information, please visit DAVA’s website located at www.davapharma.com.

FOR FURTHER INFORMATION PLEASE CONTACT:


IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
(514) 331-7440 (ext. 201)
(514) 331-0436 (FAX)
Email: horst@IntelGenx.com
Website: www.intelgenx.com